Literature DB >> 16871037

Histopathologic changes after intralesional application of phosphatidylcholine for lipoma reduction: report of a case.

Daisy Kopera1, Barbara Binder, Hermann Toplak, Helmut Kerl, Lorenzo Cerroni.   

Abstract

Phosphatidylcholine, a lecithin extracted from soy beans, is able to lower serum cholesterol to some extent. When applied intralesionally within fat tissues, it is supposed to act as a "fat burner" and reduce undesired fat deposits. We applied intralesionally phosphatidylcholine within a lipoma of a young patient. To evaluate the volume of the lipoma sonographic imaging was performed before treatment and one month after the third application. Only a partial reduction of the lipoma could be achieved, and increased echographic density could be observed after the third intralesional application of phosphatidylcholine. Surgical excision was performed. Histologic examination showed focal fibrosis, inflammatory reaction with granulomatous features, and presence of pseudomembranous degeneration of fat tissue. Off-label intralesional use of phosphatidylcholine as "fat burner" for the reduction of aesthetically disturbing lipomas should be considered only on a case-to-case basis after careful consideration of possible undesired effects similar to those described in our patient.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16871037     DOI: 10.1097/00000372-200608000-00007

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  3 in total

1.  [Injection lipolysis].

Authors:  K Hoffmann
Journal:  Hautarzt       Date:  2010-10       Impact factor: 0.751

2.  Lipolysis of a painful lipoma with ozone: the role of ultrasound in the diagnosis and quantification of the treatment.

Authors:  Özgür Kara; Murat Kara
Journal:  Med Gas Res       Date:  2019 Jul-Sep

Review 3.  The Role of Fat Reducing Agents on Adipocyte Death and Adipose Tissue Inflammation.

Authors:  Ahava Muskat; Megan Pirtle; Yana Kost; Beth N McLellan; Kosaku Shinoda
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-24       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.